{"id":5568,"date":"2018-10-05T08:11:15","date_gmt":"2018-10-05T12:11:15","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=5568"},"modified":"2018-10-05T08:12:25","modified_gmt":"2018-10-05T12:12:25","slug":"new-filings-updated-terms-ending-10-5-18","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/new-filings-updated-terms-ending-10-5-18\/","title":{"rendered":"New Filings & Updated Terms (ending 10.5.18)"},"content":{"rendered":"

This is the latest look at the IPO Pipeline including the newest filings that have registered with the SEC in the last seven days.<\/p>\n

<\/p>\n

IPO Boutique keeps apprised of the active pipeline. Currently there are 58 active IPOs in the pipeline as of October 5, \u00a02018. No SPACs or Unit Offerings are included. While the numbers may look diminished, we outlined why \u201clooks may be perceiving\u201d when it comes to the IPO pipeline\u00a0in this article.<\/strong><\/a><\/p>\n

\"\"<\/a><\/p>\n

NEW FILINGS<\/strong><\/span><\/p>\n

Company: YETI Holdings<\/strong>
\nSymbol: YETI
\nDescription: They are a rapidly growing designer, marketer, and distributor of premium products for the outdoor and recreation market.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): BofA Merrill Lynch, Morgan Stanley, Jefferies
\nCo-Manager(s): Baird, Piper Jaffray, Citigroup, Goldman Sachs, KeyBanc, William Blair, Raymond James, Stifel
\nFiled: 9-28-18
\nListed Cash Raise: $100m
\nNote: First filed in July 2016<\/p>\n

Company: Revolve Group, Inc.<\/strong>
\nSymbol: RVLV
\nDescription: REVOLVE is the next-generation fashion retailer for millennial consumers.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Morgan Stanley, Credit Suisse, BofA Merrill Lynch
\nCo-Manager(s): Barclays, Jefferies, Cowen, Guggenheim Securities, Raymond James, William Blair
\nFiled: 9-28-18
\nListed Cash Raise: $100m<\/p>\n

Company: Samoyed Holding Limited<\/strong>
\nSymbol: SMY
\nDescription: They are the only loan facilitator in China focused on facilitating credit card balance transfer products with a weighted average APR lower than 18.25%, the annual interest rate cap for credit cards set by the PRC regulators, according to Oliver Wyman.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Morgan Stanley, Deutsche Bank, CICC
\nFiled: 9-28-18
\nListed Cash Raise: $80m<\/p>\n

Company: Arog Pharmaceuticals, Inc.<\/strong>
\nSymbol: AROG
\nDescription: They are a late-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing crenolanib in indications with high unmet need.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Citigroup, RBC Capital, Nomura
\nFiled: 9-28-18
\nListed Cash Raise: $74.75m<\/p>\n

Company: NGM Biopharmaceuticals, Inc.<\/strong>
\nSymbol: NGM
\nDescription: They are a clinical-stage biopharmaceutical company developing novel therapeutics based on our scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Goldman Sachs, Citigroup, Cowen
\nFiled: 9-28-18
\nListed Cash Raise: $75m<\/p>\n

Company: Gamida Cell Ltd.<\/strong>
\nSymbol: GMDA
\nDescription: They are a clinical stage biopharmaceutical company leveraging our proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): BMO Capital, RBC Capital
\nCo-Manager(s): Needham & Co., Oppenheimer & Co.
\nFiled: 9-28-18
\nListed Cash Raise: $69m<\/p>\n

Company: StoneCo Ltd.<\/strong>
\nSymbol: STNE
\nDescription: They are a leading provider of financial technology solutions that empower merchants and integrated partners to conduct electronic commerce seamlessly across in-store, online, and mobile channels in Brazil.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Goldman Sachs, J.P. Morgan, Citigroup, Itau BBA, Credit Suisse, Morgan Stanley, BofA Merrill Lynch, BTG Pactual
\nFiled: 10-1-18
\nListed Cash Raise: $100m<\/p>\n

Company: Tencent Music Entertainment Group<\/strong>
\nSymbol: TME
\nDescription: They are the largest online music entertainment platform in China, operating the top four music mobile apps in terms of mobile MAUs in the second quarter of 2018.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): BofA Merrill Lynch, Deutsche Bank, Goldman Sachs, J.P. Morgan, Morgan Stanley (ABC order)
\nCo-Manager(s): Allen & Co., BOCI, CICC, China Renaissance, Credit Suisse, HSBC, KeyBanc Capital, Stifel (ABC order)
\nFiled: 10-2-18
\nListed Cash Raise: $1bn<\/p>\n

Company: Twist Bioscience Corporation<\/strong>
\nSymbol: TWST
\nDescription: They are a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. T
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): J.P. Morgan, Cowen
\nCo-Manager(s): Allen & Co., Baird
\nFiled: 10-3-18
\nListed Cash Raise: $86.25m<\/p>\n

Company: EnVen Energy Corporation<\/strong>
\nSymbol: ENVN
\nDescription: They are an independent oil and natural gas company engaged in the development, exploitation, exploration and acquisition of primarily crude oil properties in the deepwater region of the U.S. Gulf of Mexico.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Citigroup, J.P. Morgan, Stifel, BMO Capital
\nFiled: 10-3-18
\nListed Cash Raise: $100m<\/p>\n

Company: Orchard Rx Limited<\/strong>
\nSymbol: ORTX
\nDescription: They are a commercial-stage, fully-integrated biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): J.P. Morgan, Goldman Sachs, Cowen
\nCo-Manager: Wedbush PacGrow
\nFiled: 10-4-18
\nListed Cash Raise: $172.5m<\/p>\n

TERMS ADDED<\/strong><\/span><\/p>\n

Company: Livent Corporation<\/strong>
\nSymbol: LTHM
\nDescription: They are a pure-play, fully integrated lithium company, with a long, proven history of producing performance lithium compounds.
\nNew York.
\nTrade Date: 10\/11
\nShares: 20 million
\nPrice Range: $18.00-$20.00
\nUnderwriters: BofA Merrill Lynch, Goldman Sachs, Credit Suisse
\nCo-Manager(s): Citigroup, Loop Capital, Nomura
\nTerms Added: 10-1-18<\/p>\n

Company: Osmotica Pharmaceuticals plc<\/strong>
\nSymbol: OSMT
\nDescription: They are a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
\nTrade Date: 10\/11
\nShares: 8.3 million
\nPrice Range: $14.00-$16.00
\nUnderwriter(s): Jefferies, Barclays, RBC, Wells Fargo
\nTerms Added: 10-1-18<\/p>\n

Company: Anaplan, Inc.<\/strong>
\nSymbol: PLAN
\nDescription: Anaplan is pioneering the category of Connected Planning, which allows organizations to transform their businesses by making better and faster decisions.
\nTrade Date: 10\/12
\nShares: 15.5 million
\nPrice Range: $13.00-$15.00
\nUnderwriter(s): Goldman Sachs, Morgan Stanley, Barclays
\nCo-Manager(s): KeyBanc Capital, Canaccord Genuity, Evercore ISI, JMP Securities, Needham & Co., Piper Jaffray, SunTrust Robinson Humphrey
\nTerms Added: 10-1-18<\/p>\n

Company: Equillium, Inc.<\/strong>
\nSymbol: EQ
\nDescription: They are a biotechnology company leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need.
\nTrade Date: 10\/12
\nShares: 4.67 million
\nPrice Range: $14.00-$16.00
\nUnderwriter(s): Jefferies, Leerink, Stifel
\nTerms Added: 10-2-18<\/p>\n

Company: Allogene Therapeutics, Inc.<\/strong>
\nSymbol: ALLO
\nDescription: They are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.
\nTrade Date: 10\/11
\nShares: 16 million
\nPrice Range: $16.00-$18.00
\nUnderwriter(s): Goldman Sachs & Co, J.P. Morgan, Cowen, Jefferies
\nTerms Added: 10-2-18<\/p>\n

Company: SI-BONE, Inc.<\/strong>
\nSymbol: SIBN
\nDescription: They are a medical device company that has pioneered a proprietary minimally invasive surgical implant system, which they call iFuse, to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain.
\nTrade Date: 10\/18
\nShares: 6 million
\nPrice Range: $13.00-$15.00
\nUnderwriter(s): Morgan Stanley, BofA Merrill Lynch
\nCo-Manager(s): Canaccord Genuity, JMP Securities
\nTerms Added: 10-5-18<\/p>\n","protected":false},"excerpt":{"rendered":"

This is the latest look at the IPO Pipeline including the newest filings that have registered with the SEC in the last seven days.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[1536],"tags":[],"class_list":["post-5568","post","type-post","status-publish","format-standard","hentry","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/5568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=5568"}],"version-history":[{"count":2,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/5568\/revisions"}],"predecessor-version":[{"id":5571,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/5568\/revisions\/5571"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=5568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=5568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=5568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}